The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer-Reference-Cited by-同舟云学术

The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer

Published:2022-12 Issue:38 Volume:18 Page:4183-4192
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Rusarova Nikol¹,Vitaskova Denisa¹,Kalabova Hana¹,Ondruskova Andrea¹,Purova Dana²,Melichar Bohuslav¹,Studentova Hana¹^ORCID

Affiliation:

1. Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic

2. Olomouc University Social Health Institute, Palacky University Olomouc, Olomouc, 77900, Czech Republic

Abstract

Background: The aim of the present study was to examine the efficacy of carboplatin in combination with paclitaxel in patients with metastatic castration-resistant prostate cancer pretreated with multiple regimens including docetaxel and androgen receptor-targeted agents. Methods: Clinical data from patients treated with carboplatin plus paclitaxel were collected retrospectively from a single institution. Results: 43 patients with metastatic castration-resistant prostate cancer were identified. Median number of cycles was ten (range: 1 to 23), prostate-specific antigen response was observed in 18 (42%) patients, median progression-free survival was 115 days and median overall survival was 8.1 months. Conclusion: Combination chemotherapy using taxane with carboplatin is an effective and well-tolerated therapy in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Funder

Agentura Pro Zdravotnický Výzkum České Republiky

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0914

Reference42 articles.

1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

3. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

4. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

5. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amino Terminal Acetylation of HOXB13 Regulates the DNA Damage Response in Prostate Cancer;Cancers;2024-04-23

2. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial;Therapeutic Advances in Urology;2024-01